Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.

Zappasodi R, Merghoub T, Wolchok JD.

Cancer Cell. 2018 Apr 9;33(4):581-598. doi: 10.1016/j.ccell.2018.03.005. Review.

PMID:
29634946
2.

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.

Bai J, Gao Z, Li X, Dong L, Han W, Nie J.

Oncotarget. 2017 Nov 25;8(66):110693-110707. doi: 10.18632/oncotarget.22690. eCollection 2017 Dec 15. Review.

3.

The current status of immunobased therapies for metastatic renal-cell carcinoma.

Sathianathen NJ, Krishna S, Anderson JK, Weight CJ, Gupta S, Konety BR, Griffith TS.

Immunotargets Ther. 2017 Dec 5;6:83-93. doi: 10.2147/ITT.S134850. eCollection 2017. Review.

4.

Immune checkpoints, their control by immunotherapy and ovarian cancer.

Bose CK.

Contemp Oncol (Pozn). 2017;21(3):189-196. doi: 10.5114/wo.2017.70108. Epub 2017 Sep 29. Review.

5.

Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective.

Yu H, Paiva R, Flavell RA.

Immunology. 2018 Feb;153(2):161-170. doi: 10.1111/imm.12867. Epub 2017 Dec 11. Review.

PMID:
29155454
6.

Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses.

Zaitsu M, Issa F, Hester J, Vanhove B, Wood KJ.

JCI Insight. 2017 Oct 5;2(19). pii: 89381. doi: 10.1172/jci.insight.89381. [Epub ahead of print]

7.

Immune Checkpoint Blockers and Ovarian Cancer.

Bose CK.

Indian J Med Paediatr Oncol. 2017 Apr-Jun;38(2):182-189. doi: 10.4103/ijmpo.ijmpo_73_16. Review.

8.

Characterization of γδ T cells in patients with non-small cell lung cancer.

Bao Y, Guo L, Mo J.

Oncol Lett. 2017 Jul;14(1):1133-1140. doi: 10.3892/ol.2017.6191. Epub 2017 May 17.

9.

CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes.

Vaitaitis GM, Waid DM, Yussman MG, Wagner DH Jr.

Immunology. 2017 Oct;152(2):243-254. doi: 10.1111/imm.12761. Epub 2017 Jun 19.

PMID:
28542921
10.

The Spontaneous Autoimmune Neuromyopathy in ICOSL-/- NOD Mice Is CD4+ T-Cell and Interferon-γ Dependent.

Briet C, Bourdenet G, Rogner UC, Becourt C, Tardivel I, Drouot L, Arnoult C, do Rego JC, Prevot N, Massaad C, Boyer O, Boitard C.

Front Immunol. 2017 Mar 31;8:287. doi: 10.3389/fimmu.2017.00287. eCollection 2017.

11.

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.

Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T, Zhou A.

Cell Discov. 2017 Mar 7;3:17004. doi: 10.1038/celldisc.2017.4. eCollection 2017.

12.

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.

Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, Qi J, Wong G, Zhu X, Liu WJ, Gao S, Wang Z, Shi Y, Yang F, Gao GF, Yan J.

Nat Commun. 2017 Feb 6;8:14369. doi: 10.1038/ncomms14369.

13.

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.

Bardhan K, Anagnostou T, Boussiotis VA.

Front Immunol. 2016 Dec 12;7:550. doi: 10.3389/fimmu.2016.00550. eCollection 2016. Review.

14.

New pharmacological strategies in rheumatic diseases.

Schiotis RE, Buzoianu AD, Mureșanu DF, Suciu S.

J Med Life. 2016 Jul-Sep;9(3):227-234. Review.

15.

ProtLID, a Residue-Based Pharmacophore Approach to Identify Cognate Protein Ligands in the Immunoglobulin Superfamily.

Yap EH, Fiser A.

Structure. 2016 Dec 6;24(12):2217-2226. doi: 10.1016/j.str.2016.10.012. Epub 2016 Nov 23.

16.

Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?

Visperas A, Vignali DA.

J Immunol. 2016 Nov 15;197(10):3762-3770. Review.

17.

Efficient generation of antigen-specific CTLs by the BAFF-activated human B Lymphocytes as APCs: a novel approach for immunotherapy.

Yiwen Z, Shilin G, Yingshi C, Lishi S, Baohong L, Chao L, Linghua L, Ting P, Hui Z.

Oncotarget. 2016 Nov 22;7(47):77732-77748. doi: 10.18632/oncotarget.12792.

18.

Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Diehl R, Ferrara F, Müller C, Dreyer AY, McLeod DD, Fricke S, Boltze J.

Cell Mol Immunol. 2017 Feb;14(2):146-179. doi: 10.1038/cmi.2016.39. Epub 2016 Oct 10. Review.

19.

Modulation of Phenotype and Function of Human CD4+CD25+ T Regulatory Lymphocytes Mediated by cAMP-Elevating Agents.

Riccomi A, Gesa V, Sacchi A, De Magistris MT, Vendetti S.

Front Immunol. 2016 Sep 20;7:358. eCollection 2016.

20.

Altered Macrophage and Dendritic Cell Response in Mif-/- Mice Reveals a Role of Mif for Inflammatory-Th1 Response in Type 1 Diabetes.

Sánchez-Zamora YI, Juarez-Avelar I, Vazquez-Mendoza A, Hiriart M, Rodriguez-Sosa M.

J Diabetes Res. 2016;2016:7053963. Epub 2016 Sep 6.

Supplemental Content

Support Center